AAV8-LOX-1

AAV8-LOX-1 is a gene therapy vector that employs an adeno-associated virus serotype 8 (AAV8) to ectopically express the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in hepatocytes. The main mechanism is to promote liver-specific expression of LOX-1, thereby enhancing hepatic clearance and metabolic degradation of circulating oxidized low-density lipoprotein (Ox-LDL), a key pathogenic driver of atherosclerosis. This gene therapy is primarily targeted for the treatment and study of atherosclerosis, aiming to reduce plaque formation and inflammation by rerouting Ox-LDL metabolism from arterial wall uptake to hepatic clearance. Experimental models show that hepatic LOX-1 expression via AAV8 reduces Ox-LDL burden and atherosclerotic progression without notable hepatotoxicity[3].